New oral anticoagulants are an effective and safe alternative to vitamin K antagonists in many fields of clinical practice. The use of the direct inhibitors of activated Factor II (dabigatran) and activated Factor X (apixaban and rivaroxaban), both in patients with non-valvular atrial fibrillation (NVAF) and those with acute venous thromboembolism (VTE), is of great interest for internal medicine physicians. This paper aims to give practical guidance on management (starting therapy, follow up and bleeding complications) of patients treated with dabigatran, rivaroxaban or apixaban for NVAF or acute VTE providing practical tables concerning the phases of therapy, management of complications, drug interaction and dose adjustment if renal impairment occurs. 
Introduction
Vitamin K antagonists (VKA) interfere with the coagulation cascade through inhibition of Factors II-VII-IX-X. VKA have a slow onset of anticoagulant action, a long half-life, multiple food and drug interactions, and a very narrow therapeutic window outside of which the thrombotic and bleeding risk increases exponentially. These characteristics mean that VKA require periodical monitoring of the international normalized ratio (INR) for dose adjustments. These features have determined the exclusion of a large portion (approx. 50%) of all eligible subjects from anticoagulant therapy.
New oral anticoagulants (NOAC) have been studied in several randomized controlled trials, enrolling over 100,000 patients. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] Potential indications for NOAC include primary and secondary prevention of arterial and venous thromboembolic events. So far, these drugs (or some of them) have proven their effectiveness and safety in the prevention of venous thromboembolism (VTE) in major orthopedic surgery, 14 in the secondary prevention of acute coronary syndromes (ACS), 15 non-valvular atrial fibrillation (NVAF) [1] [2] [3] [4] and VTE [5] [6] [7] [8] [9] [10] (Tables A1 and A2 ). In particular, NVAF and VTE are frequently encountered in clinical practice by clinicians and these will receive particular attention in this paper.
The most attractive features of NOAC concern the direct and selective inhibition of a single coagulation factor (thrombin or Factor X), the fast onset of anticoagulant activity, the predictable effect, the few food and drug interactions, and the short plasma halflife. Thanks to these characteristics, the NOAC can be used at fixed dose, and they do not usually need to be monitored.
Thanks to these characteristics, and to the favorable results of phase III clinical trials, in particular in patients with NVAF and VTE, the prescription of NOAC in clinical practice is expected to increase.
This paper provides a summary of the information provided in the papers that make up this monographic issue in order to give some practical advice on management of patients treated with these new agents.
Initial treatment
Before introducing a treatment with NOAC, clinicians should check the following factors (Table A3 ).
-Clinical indications (NVAF, VTE): evaluation of the thromboembolic risk in patients with atrial fibrillation (with the CHADS-VASC2 score) (Table A4) .
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Matteo Giorgi-Pierfranceschi, 1 (Table A6 ). -Identification of the appropriate dosage (Tables A7  and A8 ) according to the data sheet for the selected drug, patient characteristics and disease type. For patients with VTE, only Xa-inhibitors (rivaroxaban and apixaban) have been approved for acute treatment with a dual intensity approach (Table A8) . Elderly subjects (>80 years of age) represent a particular population in which both cardioembolic and bleeding risk are increased, but few data are currently available regarding the use of NOAC in this kind of patients (data transferability).
The systematic assessment of all these points could help the internist to identify those patients who could benefit from NOAC treatment.
Monitoring
The pharmacological characteristics of NOAC allow the use of standardized dosages without the need for routine monitoring with coagulation tests. In general, only complete BCC, renal (plasma creatinine, creatinine clearance, Cockroft-Gault method), and hepatic function (indexes of hepatic cytolysis) are useful for monitoring patients on NOAC therapy.
According to current guidelines, 16,17 these tests should be performed before initiation of therapy, after the first three months of therapy, and then every six months. Monitoring should be planned more frequently in subjects with risk factors such as age over 80 years or altered renal function (Table A9) .
Furthermore, at each visit the following points should be considered.
-Concomitant administration of drugs that can increase or decrease the anticoagulant effect of these drugs or that contraindicate NOAC coadministration. -Adherence to the therapy (drug compliance): calculating the number of tablets taken in the period between two consecutive prescriptions and checking the boxes of medication used. -Occurrence of bleeding or thromboembolic events during treatment. -Reevaluation of indication to continue anticoagulant therapy and of the patient's risk of bleeding.
Management of bleeding events
Bleeding events are certainly the most feared complication of anticoagulant treatment. An appropriate clinical approach is mandatory according to the bleeding severity (e.g. minor, major, life-threatening). In case of any bleeding complications, it may be useful to collect information on dosage and time of last intake of the drug. Furthermore, in all the major and lifethreatening bleeding complications, the clinician should collect information on concomitant pharmacotherapy, paying particular attention to any new therapies that have been introduced that may interfere with the NOAC, such as macrolide antibiotics, antifungal agents, antiarrhythmics, antidepressants, antiepileptics, non-steroid anti-inflammatory drugs (NSAIDs) etc. (Table A10) . Evaluation of renal function with creatinine clearance calculation (in particular in patients receiving dabigatran), hepatic function and complete BCC should be performed. Finally, local measurement for assessment of hemostasis failure should be considered.
Minor bleeding
These are hemorrhagic adverse event without the characteristics of major and life-threatening bleedings. In this case, drug intake may be postponed or one dose of the drug may be skipped.
Major bleeding
According to the widely accepted International Society on Thrombosis and Hemostasis (ISTH) definition, bleeding is classified as major if it was overt and associated with a decrease in the hemoglobin level of 2 g/dL or more, required the transfusion of 2 or more units of blood, occurred into a critical site (retroperitoneal, intraocular, hemoperitoneum, hemothorax, Review spinal hematoma, hematemesis and melena, hemopericardium , hemarthrosis of the large joints), or contributed to death 18 (Table A11 ). In addition to standard supportive measurements (such as mechanical compression, surgical hemostasis, fluid replacement, and other hemodynamic support), when a major bleeding complication occurs, the clinician must withhold anticoagulant therapy. Blood volume repletion and restoration of normal platelet count (in case of thrombocytopenia ≤60×10 9 /L or thrombopathy) should be considered. Furthermore, since dabigatran is potentially dialyzable (although clinical experience is limited), dyalisis should be considered in patients treated with this drug (Table A12) .
Life-threatening bleeding
Intracranial hemorrhage or other bleeding events characterized by a decrease in hemoglobin of 5 g/dL or more, requiring transfusion of 4 units or more of packed red blood cells, and bleeding events associated with shock and hypoperfusion or requiring surgery should be considered potentially life-threatening. In this case, in addition to the standard supportive measures, it is mandatory to restore normal blood coagulation as soon as possible using, if available, (four factors) intravenous (i.v.) prothrombin concentrates (PCCs) at a dose of 50 IU/kg. 19, 20 In case of treatment failure, administration of activated prothrombin concentrate (FEIBA, Baxter) containing Factors II, VII, IX, X in inactive and active forms at a dose of 50 IU/kg (up to 200 IU/kg/day) or administration of recombinant activated Factor VII (rFVIIa: Novo Seven; 90-100 µg/kg) should be considered, although use of these compounds may be associated with a high risk of thromboembolic complications.
18,21
Tranexamic acid at a dose of 10-30 mg/kg (i.v.) may be considered as a supportive measure, although there are no clinical data on the use of this compound in patients receiving NOAC 22 (Table A13 ). In the future, since an increase in the use of NOAC is expected, protocols for the management of adverse bleeding events (periodically revised in consideration of new information from literature) should be established in each hospital. Strategies for switching to and from NOAC should also be put in place (Table  A14) .
17,23

Conclusions
New oral anticoagulants are a new treatment option particularly favorable for the management of patients with NVAF and acute VTE. Risk of thromboembolic and hemorrhagic complication should be evaluated in each patient before the introduction of an NOAC. Due to their relatively short half-life, compliance to therapy appears to be crucial, and an incorrect drug intake may result in therapeutic failure or in the occurrence of severe and potentially life-threatening adverse events. Clinician expertise in treating and monitoring acute and chronic diseases may be central to the management of these new anticoagulant drugs, helping to increase the benefits and to reduce complications of this therapy. Table A12 . Non-life-threatening major bleeding. 
